Latest research on Rosuvastatin

Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

Latest findings

Reductions in total cholesterol of 25% or more and LDL cholesterol of more than 30% or more were recorded for fixed doses of Simvastatin 40 mg, Atorvastatin 10 mg, and Rosuvastatin 5 mg and 10 mg. [source, 2003]
Of the other statins, cerivastatin has been withdrawn, and Rosuvastatin has only recently become available. [source, 2003]
Rosuvastatin produced the largest reductions in total and LDL cholesterol at 5 mg or 10 mg, though involving relatively few patients (Figure 6). [source, 2003]
Infusion pumps (Razel Scientific, Stamford, CT) were reloaded with fresh Melatonin solution every 3–4 days during the day so that any small Melatonin bolus inadvertently released during this procedure would not lengthen the programmed nighttime signal. [source, 2003]
For Rosuvastatin, a statin in the early stages of its development, information was available for 5 mg and 10 mg doses. [source, 2003]
Analyses were conducted before drug launch of Rosuvastatin in Europe. [source, 2003]
The approved dose in Holland is Rosuvastatin 10 mg daily. [source, 2003]
Additionally, information from two trials for Rosuvastatin, unpublished at the time of the searches, was provided by AstraZeneca UK. [source, 2003]
Researchers have demonstrated the effects of Rosuvastatin administration on an animal model of diabetic nephropathy. [source]
Results showed that treatment of Zucker obese rats with Rosuvastatin improved albuminuria, improved the integrity of podocyte filtration barrier, and reduced NADPH oxidase activity [77]. [source]